ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.690
0.00 (0.00%)
At close: Apr 23, 2025, 4:00 PM
2.680
-0.010 (-0.37%)
After-hours: Apr 23, 2025, 7:50 PM EDT
ImmunityBio Employees
ImmunityBio had 680 employees as of December 31, 2024. The number of employees increased by 52 or 8.28% compared to the previous year.
Employees
680
Change (1Y)
52
Growth (1Y)
8.28%
Revenue / Employee
$21,684
Profits / Employee
-$608,182
Market Cap
2.37B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 680 | 52 | 8.28% |
| Dec 31, 2023 | 628 | -97 | -13.38% |
| Dec 31, 2022 | 725 | 138 | 23.51% |
| Dec 31, 2021 | 587 | 322 | 121.51% |
| Dec 31, 2019 | 265 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
IBRX News
- 2 days ago - ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting - Business Wire
- 8 days ago - ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - Business Wire
- 15 days ago - ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor - Business Wire
- 16 days ago - ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - Business Wire
- 20 days ago - ImmunityBio: Taking Care Of Business - Seeking Alpha
- 4 weeks ago - ImmunityBio to Host Investor Day - Business Wire
- 5 weeks ago - ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching - Business Wire
- 6 weeks ago - ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum - Seeking Alpha